Placebo News and Research

RSS

Tamoxifen may help treat mania in patients with bipolar disorder

A small, three-week trial of tamoxifen, a drug typically used to treat breast cancer, indicates that it also may decrease symptoms of mania in patients with bipolar disorder, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Mar 2008

Cause of depression and anxiety unknown not chemical

The theory that depression is caused by a chemical imbalance is often presented in the media as fact even though there is little scientific evidence to support it, according to a new study co-authored by a Florida State University visiting lecturer.

4 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008

Aromatherapy and pain relief?

One of the most comprehensive investigations done to date on aromatherapy failed to show any improvement in either immune status, wound healing or pain control among people exposed to two often-touted scents.

4 Mar 2008

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).

3 Mar 2008

Turmeric for psoriasis performs no better than placebo

Anecdotal evidence touting the healing power of the Indian spice turmeric for psoriasis received a setback in a prospective study published this month by a leading dermatology journal stating that the low response rate of patients who ingested the active ingredient of the exotic spice was probably a result of the placebo effect.

1 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).

1 Mar 2008

HRT appears to have no effect on risk and severity of rheumatoid arthritis

Although rheumatoid arthritis (RA) is more predominant in women, the reasons for this are unclear.

28 Feb 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Effect of tumor necrosis factor a inhibitors on heart failure risk in rheumatoid arthritis

A chronic autoimmune disease, rheumatoid arthritis (RA) is characterized by persistent inflammation of the synovial membrane and progressive joint destruction.

28 Feb 2008

Ginkgo biloba and dementia

Taking the supplement ginkgo biloba had no clear-cut benefit on the risk of developing memory problems, according to a study published in the February 27, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.

28 Feb 2008

Antidepressants only benefit some

A new study published today in PLoS Medicine suggests that antidepressants only benefit some, very severely depressed patients.

27 Feb 2008

Anemia drug linked to blood clots, death in cancer patients

Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA: The Journal of the American Medical Association.

27 Feb 2008

Tenofovir gel safe for daily use over an extended period

A vaginal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

27 Feb 2008

Hormone therapy increases frequency of abnormal mammograms, breast biopsies

Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Feb 2008

$High calcium intake may not prevent osteoporosis and related bone fractures$

High calcium intake may not prevent osteoporosis and related bone fractures

For years, getting a lot of calcium has been portrayed as one of the best things you could do to prevent osteoporosis and related bone fractures.

26 Feb 2008

Experimental anti-HIV gel is safe for women to use on a daily basis

An experimental anti-HIV gel is safe for women to use on a daily basis, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Pittsburgh School of Medicine.

26 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

SSRI anti-depressants found to offer little clinical benefit

According to new research from Britain, new generation anti-depressants could be for many patients a waste of time and money and offer little clinical benefit.

26 Feb 2008